AR077396A2 - EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS - Google Patents
EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURASInfo
- Publication number
- AR077396A2 AR077396A2 ARP100102440A ARP100102440A AR077396A2 AR 077396 A2 AR077396 A2 AR 077396A2 AR P100102440 A ARP100102440 A AR P100102440A AR P100102440 A ARP100102440 A AR P100102440A AR 077396 A2 AR077396 A2 AR 077396A2
- Authority
- AR
- Argentina
- Prior art keywords
- hpv45
- protein
- produce
- vph45
- leaves
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan moléculas sintéticas de ADN que codifican la proteína L1 del VPH45. De manera específica, la presente proporciona polinucleotidos que codifican la proteína L1 del VPH45, en la que dichos polinucleotidos se han optimizado para los codones para un nivel elevado de expresion en una célula de levadura. Las moléculas sintéticas se pueden usar para producir partículas pseudovíricas (VLP) del VPH45, y para producir vacunas y composiciones farmacéuticas que comprenden las VLP del VPH45. Las vacunas de la presente solicitud proporcionan una inmunoprofilaxis eficaz frente a la infeccion por el virus del papiloma mediante anticuerpos neutralizantes e inmunidad celular. Vector y célula huésped que comprenden las moléculas de ADN. Procedimiento para producir las VLP.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50681203P | 2003-09-29 | 2003-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077396A2 true AR077396A2 (es) | 2011-08-24 |
Family
ID=34421558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103420A AR045804A1 (es) | 2003-09-29 | 2004-09-22 | Expresion optimizada de l1 del vph45 en levaduras |
| ARP100102440A AR077396A2 (es) | 2003-09-29 | 2010-07-07 | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103420A AR045804A1 (es) | 2003-09-29 | 2004-09-22 | Expresion optimizada de l1 del vph45 en levaduras |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7250170B2 (es) |
| EP (1) | EP1673106B1 (es) |
| JP (4) | JP5451960B2 (es) |
| KR (1) | KR101165278B1 (es) |
| CN (1) | CN1859923B (es) |
| AR (2) | AR045804A1 (es) |
| AT (1) | ATE435029T1 (es) |
| AU (1) | AU2004277934B2 (es) |
| BE (1) | BE2015C072I2 (es) |
| BR (1) | BRPI0414845B8 (es) |
| CA (1) | CA2539168C (es) |
| CY (2) | CY1110525T1 (es) |
| DE (1) | DE602004021828D1 (es) |
| DK (1) | DK1673106T3 (es) |
| ES (1) | ES2327530T3 (es) |
| FR (1) | FR15C0083I2 (es) |
| HU (1) | HUS1500063I1 (es) |
| IL (1) | IL174458A (es) |
| IS (1) | IS2694B (es) |
| LT (2) | LTC1673106I2 (es) |
| LU (1) | LU92902I2 (es) |
| MX (1) | MXPA06003457A (es) |
| MY (1) | MY140664A (es) |
| NL (1) | NL300776I2 (es) |
| NO (3) | NO339932B1 (es) |
| NZ (1) | NZ545834A (es) |
| PL (1) | PL1673106T3 (es) |
| PT (1) | PT1673106E (es) |
| RU (1) | RU2360001C2 (es) |
| SI (1) | SI1673106T1 (es) |
| TW (1) | TWI350853B (es) |
| WO (1) | WO2005032586A1 (es) |
| ZA (1) | ZA200601961B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| CA2560487C (en) | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| EP1877086A2 (en) * | 2005-04-26 | 2008-01-16 | GlaxoSmithKline Biologicals SA | Vaccine |
| EP2059262B1 (en) * | 2006-08-28 | 2013-08-21 | Sungkyunkwan University Foundation for Corporate Collaboration | A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein |
| CA2679720A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| MY162658A (en) * | 2007-11-23 | 2017-06-30 | Shanghai Zerun Biotechnology Co Ltd | Genes encoding major capsid protein l1 of human papilloma virus and use of the same |
| CN102215861B (zh) | 2009-06-19 | 2014-10-08 | 艾金株式会社 | 宫颈癌疫苗 |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| JP6001064B2 (ja) | 2011-06-15 | 2016-10-05 | チュンアン ユニバーシティー インダストリー アカデミック コアポレイション ファウンデイション | ヒトパピローマウイルスｌ１タンパク質の生産収率を向上させる方法 |
| JP6050811B2 (ja) | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法 |
| CN103215302B (zh) * | 2012-01-21 | 2019-01-15 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv18 l1蛋白的方法 |
| CN108624614A (zh) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
| CN110484554B (zh) * | 2013-04-26 | 2024-04-16 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
| CN110295190A (zh) * | 2013-05-17 | 2019-10-01 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 |
| CN104513826B (zh) * | 2013-09-29 | 2020-10-20 | 上海泽润生物科技有限公司 | 人乳头瘤病毒基因,及载体,菌株,表达方法 |
| EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| AR101840A1 (es) * | 2014-09-11 | 2017-01-18 | Cadila Healthcare Ltd | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene |
| CN106282278B (zh) * | 2015-06-29 | 2021-06-08 | 广东东阳光药业有限公司 | 一种人乳头瘤病毒l1蛋白的发酵方法 |
| CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750050B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒45亚型蛋白表达 |
| JOP20220187A1 (ar) | 2020-02-14 | 2023-01-30 | Merck Sharp And Dohme Llc | لقاح فيروس الورم الحليمي البشري (hpv) |
| CN112680462B (zh) * | 2020-12-29 | 2022-02-22 | 上海博唯生物科技有限公司 | 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
| CN118019547A (zh) | 2021-08-19 | 2024-05-10 | 默沙东有限责任公司 | 热稳定脂质纳米粒子及其使用方法 |
| US20240408188A1 (en) | 2023-06-09 | 2024-12-12 | Merck Sharp & Dohme Llc | Nanoemulsion adjuvant compositions for human papillomavirus vaccines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0757717B1 (en) * | 1994-05-16 | 2006-05-31 | Merck & Co. Inc. | Papillomavirus vaccines |
| AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| CN1252075A (zh) | 1997-02-07 | 2000-05-03 | 麦克公司 | 合成的hiv gag基因 |
| AU734761B2 (en) * | 1997-05-27 | 2001-06-21 | Hanil Synthetic Fiber Co., Ltd. | Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| CA2339324C (en) * | 1998-08-14 | 2011-05-31 | Robert S. Lowe | Protein delivery system using human papillomavirus virus-like particles |
| AU760633B2 (en) * | 1998-08-14 | 2003-05-22 | Merck Sharp & Dohme Corp. | Process for purifying human papillomavirus virus-like particles |
| US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| ATE290013T1 (de) * | 1998-12-23 | 2005-03-15 | Merck & Co Inc | Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet |
| ATE284898T1 (de) * | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
| US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| HK1056195B (en) | 2000-07-21 | 2007-06-22 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
| US20040063188A1 (en) * | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| MXPA05010285A (es) | 2003-03-24 | 2005-11-17 | Merck & Co Inc | Expresion optimizada de hpv 31 l1 en levadura. |
-
2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh not_active IP Right Cessation
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh not_active Expired - Lifetime
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en not_active IP Right Cessation
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de not_active Expired - Lifetime
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 US US10/573,330 patent/US7250170B2/en not_active Expired - Lifetime
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en not_active Expired - Lifetime
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en not_active Ceased
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko not_active Expired - Lifetime
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja not_active Expired - Lifetime
- 2004-09-24 CA CA2539168A patent/CA2539168C/en not_active Expired - Lifetime
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt not_active IP Right Cessation
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es not_active Expired - Lifetime
-
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
-
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
-
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
-
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
-
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
-
2015
- 2015-11-30 NL NL300776C patent/NL300776I2/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I1/el unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
-
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
-
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown
-
2022
- 2022-11-30 NO NO2022051C patent/NO2022051I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
| AR046835A1 (es) | Expresion optimizada de l1 de hpv58 en levadura | |
| ECSP056032A (es) | Expresión optimizada de hpv 31 l1 en levadura | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| PE20201264A1 (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas | |
| SG165378A1 (en) | Functional influenza virus-like particles (vlps) | |
| AR048191A1 (es) | Expresion optimizada de hpv 52 l1 en levaduras | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| WO2008034388A8 (en) | Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof | |
| EA201170965A1 (ru) | Усовершенствованные вакцины вируса человеческой папилломы и способы их использования | |
| EP2589604A4 (en) | SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS | |
| AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
| AR045815A1 (es) | Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano | |
| TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
| BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma | |
| TH82139B (th) | การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |